1785 – Dexcom ONE continuous glucose monitoring system for people with insulin dependent type 2 diabetes

National Diabetes Service Scheme funding.

Dexcom ONE is a real time continuous glucose monitoring (RT-CGM) system consisting of a wearable sensor and transmitter which transmits data to a compatible smart device via a mobile application. Continuous monitoring allows people with type 2 diabetes (T2D) to accurately monitor their blood glucose levels in real time, helping them make informed decisions to manage their condition and reduce the risk of diabetes-related complications.

Type: Investigative technology

T2D is a condition in which the body becomes resistant to the normal effects of insulin and gradually loses the capacity to produce enough insulin in the pancreas. This leads to high blood sugar (glucose) levels. T2D is the most common form of diabetes and is more likely to occur in those with a family history of the condition, although its development can also be associated with lifestyle factors.

Initially, T2D can often be managed with lifestyle modification such as healthy eating and regular exercise. However, many people with T2D will also need to take medication and many eventually require insulin injections to reduce the complications associated with the condition such as nerve damage, kidney disease and heart disease.

For the second consideration of this application by MSAC, the applicant has included evidence for two additional populations:

• people with gestational diabetes and
• people with type 3c or ‘other’ diabetes.

As these populations were not included in the original submission, they were not considered by MSAC in July 2025, and are not directly referred to in the Public Summary Document. As such, questions about these populations are not in the consultation survey. However, if stakeholders wish to comment on these populations, they are encouraged to do so in the final section of the survey. This new information will be considered by MSAC at the meeting.

• PASC consultation: Bypassing PASC
• MSAC consultation: Closed Friday 12 June 2026 11:59 pm AEST  

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the application is addressing.

Find out more about consultation.

• PASC meeting: 12–13 December 2024
• ESC meeting:
  • 12 - 13 June 2025
  • 11 to 12 June 2026
• MSAC meeting:
  • 31 July - 1 August 2025
  • 30 to 31 July 2026
• Stakeholder meeting: 20 May 2026
  An MSAC Stakeholder meeting was held with clinicians to discuss uncertainties with continuous glucose monitoring for people with insulin dependent type 2 diabetes, gestational diabetes, and other types of diabetes similar to type 1 (such as type 3c diabetes). The meeting was not an MSAC decision forum, but an opportunity to seek clinician input on issues raised by MSAC during its July/August 2025 consideration of MSAC applications 1785 and 1786. The outcomes are published above.

Find out more about our meetings. 

Find out more about:

• the MSAC process
• application types
• application timelines.